GoKawiilRevolution Medicines' daraxonrasib shows promise against pancreatic cancer driver mutations
Revolution Medicines has developed daraxonrasib, described as the first drug able to broadly target a key genetic driver behind pancreatic cancer. The compound is reported to work against a range of mutations previously considered difficult to treat with a single therapy.